Entrada Therapeutics, Inc.
TRDA · XNASCIK 1689375fmd_0JZ7EE7MDDAD4AC6WS4WYM2BRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 129 | 211 | 25 |
| Research and development | 21 | 36 | 67 | 100 | 125 | 142 |
| Total operating expenses | 27 | 51 | 97 | 132 | 164 | 183 |
| Operating income | (27) | (51) | (97) | (3) | 47 | (158) |
| Other non-operating income (expense) | 0 | (0) | 3 | 15 | 19 | 15 |
| Income tax expense | 0 | 0 | 0 | 19 | 1 | 1 |
| Net income | (27) | (51) | (95) | (7) | 66 | (144) |